Nusinersen (Spinraza)

Covered for pediatric/adult SMA with documented bi‑allelic SMN1 mutations and either 2–3 SMN2 copies (or ≥4 SMN2 copies only if symptomatic consistent with Type 1–3 SMA), and expressly excludes prior recipients of onasemnogene abeparvovec (Zolgensma). Requires prescription/consultation by an SMA/neuromuscular specialist, pre‑administration labs (PT/APTT, platelet count, quantitative urine protein), adherence to intrathecal dosing (4 loading doses then every 4 months), 12‑month authorizations, and documented clinical response for re‑authorization.

"Spinraza is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients."

Sign up to see full coverage criteria, indications, and limitations.